Wolf-henning Prof. Dr. Boehncke
#148,982
Most Influential Person Now
Wolf-henning Prof. Dr. Boehncke's AcademicInfluence.com Rankings
Wolf-henning Prof. Dr. Boehnckephilosophy Degrees
Philosophy
#8148
World Rank
#11474
Historical Rank
Logic
#5178
World Rank
#6556
Historical Rank

Download Badge
Philosophy
Wolf-henning Prof. Dr. Boehncke's Degrees
- Doctorate Medicine University of Cologne
Why Is Wolf-henning Prof. Dr. Boehncke Influential?
(Suggest an Edit or Addition)Wolf-henning Prof. Dr. Boehncke's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Treatment recommendations for psoriatic arthritis (2008) (796)
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis (2016) (764)
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (2020) (433)
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity (2011) (431)
- Psoriasis: a possible risk factor for development of coronary artery calcification (2007) (359)
- S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update (2012) (259)
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis (2018) (255)
- The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond (2018) (249)
- Psoriasis patients show signs of insulin resistance (2007) (239)
- Proteasome inhibition: a new anti-inflammatory strategy (2003) (231)
- Biological therapies in the systemic management of psoriasis: International Consensus Conference (2004) (214)
- Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. (2004) (198)
- The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis (2017) (172)
- Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences (2018) (171)
- Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial (2020) (145)
- Etiology and Pathogenesis of Psoriasis. (2015) (140)
- Pulling the trigger on psoriasis (1996) (137)
- The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. (2003) (136)
- Treatment of psoriasis by topical photodynamic therapy with polychromatic light (1994) (135)
- Managing comorbid disease in patients with psoriasis (2010) (132)
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study (2018) (130)
- Mycophenolate mofetil is effective in the treatment of atopic dermatitis. (2001) (126)
- Excess β2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules (1991) (125)
- Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. (2004) (123)
- Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation (2002) (120)
- Effective continuous systemic therapy of severe plaque‐type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study (2011) (120)
- The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. (1993) (119)
- Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. (1996) (119)
- Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. (2002) (117)
- Is psoriasis a T‐cell disease? (2000) (111)
- Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. (2002) (111)
- S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment (2018) (111)
- Burden of Disease: Psoriasis and Psoriatic Arthritis (2013) (110)
- The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo (2006) (109)
- German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version) (2007) (109)
- Specific TRPC6 Channel Activation, a Novel Approach to Stimulate Keratinocyte Differentiation* (2008) (107)
- Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. (2005) (101)
- German S3-guidelines on the treatment of psoriasis vulgaris (short version) (2012) (100)
- IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications (2020) (99)
- Biologic therapies for psoriasis. A systematic review. (2006) (96)
- Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris (1999) (95)
- Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris (2007) (94)
- S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011 (2011) (90)
- Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. (2012) (86)
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement (2020) (85)
- Incidence and causes of heparin-induced skin lesions (2009) (83)
- German psoriasis registry PsoBest: objectives, methodology and baseline data (2014) (79)
- Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis (2014) (77)
- Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. (1993) (77)
- Systemic photodynamic therapy is a safe and effective treatment for psoriasis. (2000) (75)
- Reduced TRPC Channel Expression in Psoriatic Keratinocytes Is Associated with Impaired Differentiation and Enhanced Proliferation (2011) (71)
- Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus (2018) (71)
- P-selectin (2007) (71)
- Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial (2011) (69)
- Therapy of psoriasis in childhood and adolescence ‐ a German expert consensus (2011) (68)
- Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis. (2016) (68)
- Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. (2002) (66)
- Calcipotriol Solution for the Treatment of Scalp Psoriasis: Evaluation of Efficacy, Safety and Acceptance in 3,396 Patients (2001) (66)
- Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives (2012) (66)
- Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. (2000) (64)
- Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. (2002) (63)
- Efficacy of dexpanthenol in skin protection against irritation: a double‐blind, placebo‐controlled study (2003) (62)
- Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. (2004) (62)
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 (2015) (61)
- Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. (2008) (61)
- Platelet P‐selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis (2009) (60)
- Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice (2019) (59)
- Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the β-Sheet Structure of MIF* (2012) (58)
- Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin (2013) (56)
- Leg ulcers in Klinefelter's syndrome – further evidence for an involvement of plasminogen activator inhibitor‐1 (1997) (56)
- Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides (2005) (55)
- Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment (2018) (55)
- Anti‐inflammatory effects of the GABAB receptor agonist baclofen in allergic contact dermatitis (2010) (55)
- Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience (2015) (55)
- Juvenile psoriasis and its clinical management: a European expert group consensus (2010) (55)
- Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo (2004) (55)
- Heparin-induced skin lesions (2012) (53)
- Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation (2017) (52)
- The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. (2006) (51)
- Junctional adhesion molecule (JAM)‐B supports lymphocyte rolling and adhesion through interaction with α4β1 integrin (2009) (50)
- Induction of psoriasiform inflammation by a bacterial superantigen in the SCID‐hu xenogeneic transplantation model (1997) (49)
- IL-25 (IL-17E) in epithelial immunology and pathophysiology. (2021) (48)
- Allergic contact dermatitis from black cumin (Nigella sativa) oil‐containing ointment (2002) (47)
- Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus (2006) (47)
- Management of cutaneous type IV hypersensitivity reactions induced by heparin (2006) (47)
- Immunogenicity of biologic therapies: causes and consequences (2018) (46)
- Tolerance to intravenous admiration of heparin and heparinoid in a patient with delayed‐type hypersensitivity to heparins and heparinoids (1996) (46)
- Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia (2010) (44)
- Swiss clinical practice guidelines on field cancerization of the skin. (2014) (43)
- S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations (2018) (43)
- Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature (2007) (42)
- Efalizumab in the treatment of psoriasis (2007) (42)
- Endogenous μ‐opioid peptides modulate immune response towards malignant melanoma (2011) (42)
- T-Cell-Receptor Repertoire in Chronic Plaque-Stage Psoriasis Is Restricted and Lacks Enrichment of Superantigen-Associated Vβ Regions (1995) (41)
- Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. (2013) (41)
- Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice (2004) (40)
- The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs (1999) (39)
- Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans (2003) (39)
- Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris (2016) (38)
- Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure (2019) (38)
- Psoriasis – a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives (2009) (38)
- Clonal disease in early cutaneous T-cell lymphoma. (1994) (38)
- Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. (2007) (38)
- Ethanol metabolite acetic acid as causative agent for type‐I hypersensitivity‐like reactions to alcohohc beverages (1996) (37)
- High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. (2013) (37)
- Differential expression of heat shock protein 70 (HSP70) and heat shock cognate protein 70 (HSC70) in human epidermis (2004) (36)
- Role of beta 1-integrins in epidermotropism of malignant T cells. (1992) (36)
- Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease (2013) (36)
- Autoreactive T-Lymphocytes in Inflammatory Skin Diseases (2019) (36)
- Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey (2018) (36)
- A Subset of Macrophages Located along the Basement Membrane (“Lining Cells”) Is a Characteristic Histopathological Feature of Psoriasis (1995) (36)
- Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients (2019) (36)
- IL-22 capacitates dermal fibroblast responses to TNF in scleroderma (2015) (36)
- Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E‐ and P‐selectin, VCAM‐1 and PECAM‐1 (2010) (35)
- Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo (2005) (35)
- Eosinophilic cellulitis (Wells' syndrome) associated with colon carcinoma (2005) (35)
- Differential expression of adhesion molecules on infiltrating cells in inflammatory dermatoses. (1992) (34)
- IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. (2019) (33)
- Diagnosing and treating psoriatic arthritis: an update (2014) (33)
- Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice (2001) (33)
- Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders? (2003) (32)
- Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. (2006) (32)
- [S3-Guidelines for the therapy of psoriasis vulgaris]. (2006) (32)
- Photodynamic tumor therapy and on-line fluorescence spectroscopy after ALA administration using 633-nm light as therapeutic and fluorescence excitation radiation (1994) (32)
- PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. (2009) (32)
- Low allergenic potential with fondaparinux: results of a prospective investigation. (2010) (31)
- Reproducible identification of the causative drug of a fixed drug eruption by oral provocation and lesional patch testing (2002) (31)
- In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma. (1994) (31)
- Immunomodulatory drugs for psoriasis (2003) (30)
- Allergic contact dermatitis from benzyl alcohol during topical antimycotic treatment (1999) (30)
- Leukocyte extravasation as a target for anti‐inflammatory therapy – Which molecule to choose? (2005) (29)
- Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting (2011) (29)
- Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation (2002) (29)
- Psoriasis and bacterial superantigens--formal or causal correlation? (1996) (29)
- The SCID-hu xenogeneic transplantation model: complex but telling (1999) (28)
- Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies. (2019) (28)
- Expression of the basal cell adhesion molecule (B‐CAM) in normal and diseased human skin (2000) (28)
- Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions. (2007) (28)
- Cost‐effectiveness of psoriasis therapy with etanercept in Germany (2007) (27)
- Cytokines of the IL‐17 family in psoriasis (2020) (27)
- Influence of activation and differentiation of cells on the effectiveness of photodynamic therapy. (1995) (27)
- Clinical and pathophysiological aspects of hydroxyethyl starch-induced pruritus: evaluation of 96 cases. (1996) (27)
- Safety and efficacy of alefacept in elderly patients and other special populations. (2005) (27)
- Intolerance of fondaparinux in a patient allergic to heparins (2004) (27)
- Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT (2017) (27)
- Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis (2021) (26)
- Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced (2021) (26)
- Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line (2019) (25)
- Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy (2011) (25)
- Comparison of sensitivity towards photodynamic therapy of cutaneous resident and infiltrating cell types in vitro (1996) (25)
- OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study (2017) (25)
- More than skin-deep: the many dimensions of the psoriatic disease. (2014) (25)
- The Western blot is a highly sensitive and efficient technique in diagnosing allergy to wasp venom (2001) (24)
- IL‐17A localizes in the exocytic compartment of mast cells in psoriatic skin (2017) (24)
- Topical photodynamic therapy using methylene blue and 5-aminolaevulinic acid in psoriasis (1997) (24)
- The risk for cross‐reactions after a cutaneous delayed‐type hypersensitivity reaction to heparin preparations is independent of their molecular weight: a systematic review (2011) (23)
- Circadian clocks guide dendritic cells into skin lymphatics (2021) (23)
- Interactive large-group teaching in a dermatology course (2006) (23)
- T‐cell receptor β variable region (Vβ) usage in cutaneous T‐cell lymphomas (CTCL) in comparison to normal and eczematous skin (1996) (23)
- Allergic contact dermatitis from diphenylthiourea in a Wet suit (1997) (23)
- Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting (2013) (22)
- PAX2 Regulates ADAM10 Expression and Mediates Anchorage-Independent Cell Growth of Melanoma Cells (2011) (21)
- Type‐IV hypersensitivity to topical estradiol in a patient tolerant to it orally (1996) (21)
- Benzoyl peroxide as a contact allergen in adhesive tape (1999) (21)
- Psoriasis and risk of myocardial infarction. (2007) (21)
- Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases (2005) (21)
- Psoriasis: Clinical manifestations, pathogenesis and therapeutic perspectives. (2005) (20)
- Benchmarking Care in Psoriatic Arthritis — The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting (2017) (20)
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. (2020) (20)
- ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma. (2010) (20)
- Structure-function relation of efomycines, a family of small-molecule inhibitors of selectin functions. (2006) (20)
- New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease (2014) (19)
- The psoriasis SCID mouse model: a tool for drug discovery? (2005) (19)
- Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T‐cell receptor‐repertoire among infiltrating lymphocytes (1997) (19)
- The superantigen exfoliative toxin induces cutaneous lymphocyte-associated antigen expression in peripheral human T lymphocytes. (1996) (19)
- Analysis of TAP2 and HLA-DP gene polymorphism in psoriasis. (1994) (19)
- The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting (2014) (19)
- Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis (2019) (19)
- [Endurance capabilities of triathlon competitors with type 1 diabetes mellitus]. (2009) (19)
- Quality indicators in psoriatic arthritis. (2007) (19)
- Targeting selectin functions in the therapy of psoriasis. (2004) (18)
- Occupational protein contact dermatitis caused by meat and fish. (1998) (18)
- [Comorbidity in psoriasis]. (2016) (18)
- Predominant usage of distinct T‐cell receptor Vβ regions by epidermotropic T cells in psoriasis (1994) (18)
- Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin? (2016) (17)
- German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations (2021) (17)
- IL-17E (IL-25) and IL-17A differentially affect the functions of human keratinocytes. (2020) (17)
- Leukocyte adhesion: a suitable target for anti-inflammatory drugs. (2006) (17)
- Platelet, not endothelial, P-selectin expression contributes to generation of immunity in cutaneous contact hypersensitivity. (2010) (17)
- Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin (2008) (17)
- Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. (2008) (16)
- Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study (2020) (16)
- Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults (2020) (16)
- Demonstration of Clonal Disease in Early Mycosis Fungoides (1992) (16)
- Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis–severe combined immunodeficient mouse model (2005) (15)
- Superantigens but not mitogens are capable of inducing upregulation of E‐selectin ligands on human T lymphocytes (1997) (15)
- Prospective randomised comparison of traditional, personal bedside and problem‐oriented practical dermatology courses (2004) (15)
- Delayed-type hypersensitivity reaction to kava-kava extract. (2000) (15)
- Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry (2017) (15)
- Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review (2014) (14)
- Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab” (2010) (14)
- Reversal of murine epidermal atrophy by topical modulation of calcium signaling. (2014) (14)
- Targeted cutaneous delivery of etanercept using Er:YAG fractional laser ablation. (2020) (14)
- The selective cyclooxygenase‐2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria (2003) (14)
- The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists (2015) (13)
- [Osteoma cutis. Multiple miliary osteoma of the face]. (1993) (13)
- Insulin Resistance May Contribute to Upregulation of Adhesion Molecules on Endothelial Cells in Psoriatic Plaques. (2016) (13)
- Interleukin-38 interacts with destrin/actin-depolymerizing factor in human keratinocytes (2019) (13)
- Eukaryotic expression of the broad‐spectrum chemokine receptor antagonist vMIP‐II and its effects on T‐cell function in vitro and in vivo (2006) (13)
- Type I and type II psoriasis show a similar usage of T-cell receptor variable regions. (1991) (12)
- Biologics in General Medicine (2007) (12)
- Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey (2020) (12)
- Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience. (2012) (12)
- Recognition of early melanoma: a monocentric dermoscopy follow‐up study comparing de novo melanoma with nevus‐associated melanoma (2018) (12)
- C-type particles are inducible in Se-Ax, a continuous T-cell line from a patient with Sézary's syndrome (2004) (12)
- German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations (2021) (11)
- Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies (2020) (11)
- [New information about fumaric acid esters (Fumaderm): results of a workshop of experts]. (2011) (11)
- Diagnosis of heparin-induced delayed type hypersensitivity (2010) (11)
- Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis (2021) (11)
- Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2013) (11)
- Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care (2020) (11)
- Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study (2011) (11)
- Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissue‐Engineered Scleroderma Epidermis (2021) (11)
- The T-cell receptor Vβ repertoire of nickel-specific T cells (1998) (10)
- The influence of heparin’s molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514–17 (2008) (10)
- Chronic venous insufficiency – a potential trigger for localized scleroderma (2006) (10)
- Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model. (2001) (10)
- Endothelial cells are highly heterogeneous at the level of cytokine‐induced insulin resistance (2013) (10)
- Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study (2018) (10)
- EADV preceptorship: advances in dermatology (2010) (10)
- OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study (2018) (10)
- Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting (2012) (10)
- The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development (2019) (9)
- Evidence for a Pathway Independent from 2′‐Deoxyguanosine and Reversible by IL‐2 by which Purine Nucleoside Phosphorylase Inhibitors Block T‐Cell Proliferation (1994) (9)
- Dermal adipocytes’ claim for fame in psoriasis (2017) (9)
- Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2014) (9)
- Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross‐sectional, multi‐country, observational study (2020) (9)
- Urticaria associated with a small cell carcinoma of the lung. (2002) (9)
- Monitoring of phagocytic activity in histiocytic cytophagic panniculitis. (2001) (9)
- Managing comorbidities in psoriasis. (2009) (9)
- T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin. (1996) (9)
- [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)]. (2005) (8)
- Constitutive and functionally relevant expression of JAM-C on platelets (2010) (8)
- Computer‐aided analysis of cell interactions under dynamic flow conditions (2009) (8)
- Ablative techniques in Psoriasis vulgaris resistant to conventional therapies. (1999) (8)
- Low incidence of heparin‐induced skin lesions in orthopedic surgery patients with low‐molecular‐weight heparins (2018) (8)
- Psoriasis treatment: current and emerging directed therapies. Discussion (2005) (8)
- Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study * (2021) (8)
- NAGELLACK-ALLERGIE: EINE WICHTIGE DIFFERENTIALDIAGNOSE BEI KONTAKTDERMATITIS (2008) (8)
- Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition (2017) (8)
- Intolerance to sodium metabisulfite in beer (1996) (8)
- Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2015) (7)
- Discrimination between immunoaccessory and phagocytic monocytes/macrophages of the skin in paraffin‐embedded tissue by the monoclonal antibody Ki‐M1P (1993) (7)
- Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial (2020) (7)
- T-cell-receptor repertoire in chronic plaque-stage psoriasis is restricted and lacks enrichment of superantigen-associated V beta regions. (1995) (7)
- Chapter 16 Topical photodynamic therapy for psoriasis (2001) (7)
- Complicated mycosis fungoides mimicking facial erysipelas (2005) (7)
- Eyelid dermatitis caused by an eyelash former (2005) (7)
- IL‐38 orchestrates proliferation and differentiation in human keratinocytes (2022) (7)
- Fixed drug eruption caused by articain (2004) (6)
- Psoriatic Arthritis and Psoriasis (2016) (6)
- Viewpoint 1 (2005) (6)
- Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care (2020) (6)
- The alpha-defensins HNP-1 and HNP-2 are dominant self-peptides presented by HLA class-II molecules in lesional psoriatic skin. (2004) (6)
- Graft persistence in animal models of psoriasis (1997) (6)
- Perspective: Don't be superficial (2012) (6)
- Biosimilars for Psoriasis—Experience from Europe (2019) (5)
- Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". (2010) (5)
- Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2016) (5)
- Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies (2022) (5)
- Delayed‐type reactivity to catcipotriol without cross‐sensitization to tacalcitol (1997) (5)
- Kutane Botryomykose (2007) (5)
- Mechanotransduction in Skin Inflammation (2022) (5)
- Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial (2019) (5)
- [Nail polish allergy. An important differential diagnosis in contact dermatitis]. (1997) (5)
- Heavy naphthen oil exhibits antipsoriatic efficacy in vivo and antiproliferative as well as differentiation-inducing effects on keratinocytes in vitro. (2000) (5)
- [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents]. (2001) (5)
- Research in practice: the systemic aspects of psoriasis (2008) (5)
- [Cutaneous botryomycosis. A rarely diagnosed bacterial infection of the skin]. (2007) (5)
- New biologics in psoriasis – progress and problems (2017) (5)
- Discussion: Assessment of psoriatic arthritis (2005) (5)
- Photodynamic tumor therapy and on-line fluorescence spectroscopy after aminolevulinic acid administration using 633-nm light as therapeutic and fluorescence excitation radiation (1994) (4)
- Biologic effects of bacterial superantigens in a xenogeneic transplantation model for psoriasis. (2001) (4)
- GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venerology Meeting, Verona, 2012: A Meeting Report (2013) (4)
- In-vivo remission spectroscopy on tattoos and topically applied photosensitizers in man (1994) (4)
- [New insights into fumaric acid esters (Fumaderm ®):results of the 2nd Expert Workshops]. (2012) (4)
- [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs]. (2003) (4)
- Anaphylaxis to red currants (2000) (4)
- Introduction: Definition and Classification of Biologics (2007) (4)
- Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation (2002) (4)
- GRAPPA 2013 Basic/Translational/Clinical Science Update: Comorbidity Monitoring (2014) (4)
- [Beyond immunopathogenesis. Insulin resistance and "epidermal dysfunction"]. (2012) (4)
- GRAPPA 2015 Research and Education Project Reports (2016) (4)
- Tolerance to a group C corticosteroid systemically in a patient with delayed‐type hypersensitivity to group A systemic corticosteroids (2002) (4)
- Warning Shot (2001) (4)
- [Modern therapy of psoriasis : evidence-based, patient-centered, goal-oriented]. (2012) (4)
- ‘Upgrading’ psoriasis responsibly (2014) (4)
- Systemic antipsoriatic therapy may reverse endothelial dysfunction (2011) (3)
- Initiative for quality in psoriasis and psoriatic arthritis. (2008) (3)
- Plasma cells in the dermal infiltrate of mycosis fungoides are of polyclonal origin. (1989) (3)
- Primary subcutaneous leiomyosarcoma exhibiting the characteristic immunophenotype positive for vimentin and desmin. (1994) (3)
- GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report (2014) (3)
- Efficacy and Safety of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study (2017) (3)
- Epidermal insulin resistance as a therapeutic target in acanthosis nigricans? (2014) (3)
- Best-practice Indicators in Psoriatic Disease Care (2019) (3)
- A majority of proliferating T cells in cutaneous malignant T cell lymphomas may lack the high affinity IL-2 receptor (CD25) (2005) (3)
- GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting (2018) (3)
- Effects of rofecoxib, celecoxib, and parecoxib on anti‐IgE‐induced histamine release from human skin mast cells and basophils (2003) (3)
- AB0820 COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (2020) (3)
- Adipose-Derived Stromal Cells for Chronic Wounds: Scientific Evidence and Roadmap Toward Clinical Practice (2022) (3)
- Photodynamic effects on T-cells and skin lesions of a patient with mycosis fungoides using porphyrin photosensitizers (1994) (3)
- [Treatment recommendations for psoriatic arthritis]. (2009) (3)
- LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan (2021) (2)
- Interleukin‐17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses (2021) (2)
- GRAPPA Trainees Symposium 2018: A Report from the GRAPPA 2018 Annual Meeting (2019) (2)
- Etanercept: a soluble TNF-a receptor in the treatment of psoriasis (2007) (2)
- Presidential Round Table: A Report from the GRAPPA Annual Meeting (2016) (2)
- Clinical long‐term studies: data collection and assessment (2011) (2)
- Assessment of publications using methods of evidence‐based medicine: an introduction using a dermatological clinical study (2007) (2)
- SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED (2020) (2)
- [Psoriasis in the animal model]. (1997) (2)
- [Chronic leg ulcers and Pseudomonas aeruginosa infection]. (2015) (2)
- Pathogenesis-oriented therapy of psoriasis using biologics (2022) (2)
- IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in Systemic Sclerosis epidermis. (2022) (2)
- 15281 Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study (2020) (2)
- Comparitive in vitro effects of mono- and polychromatic photodynamic therapy on malignant transformed B- and T-cells (1993) (2)
- [To be or not to be: another round in the discussion of the role of psoriasis as a risk factor for associated diseases]. (2013) (2)
- [Human to mouse xenotransplantation models complement transgenic and know-out mice. Comment on the contribution by K. Sellheyser: Transgenic mice as models for skin diseases]. (1996) (2)
- SAT0344 The effect of guselkumab on enthesitis: results from a phase 2 study in patients with active psoriatic arthritis (2018) (2)
- GRAPPA Trainees Symposium 2019: A Report from the GRAPPA 2019 Annual Meeting (2020) (1)
- Peak and baseline concentrations of fondaparinux during prophylactic therapy (2011) (1)
- P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study (2020) (1)
- Expression of the basal cell adhesion molecule (B-CAM) in human epidermis (1998) (1)
- Summary of Minutes of the GRAPPA Meeting Adjacent to the American Academy of Dermatology 67th Annual Meeting (2011) (1)
- Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis. (2023) (1)
- Psoriasis assessment tools in clinical trials. Discussion (2005) (1)
- AB0753 COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH GUSELKUMAB (2019) (1)
- GRAPPA Fellows Symposium Adjacent to the Swiss Psoriasis Day, Geneva, 2014: A Meeting Report (2015) (1)
- FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS (2020) (1)
- In vivo reflectance confocal microscopy: a useful non-invasive tool to assess the response to isolated limb perfusion for superficial pigmented melanoma in-transit metastatic disease. Report of a case (2017) (1)
- Lymphocyte homing to the skin : immunology, immunopathology, and therapeutic perspectives (2004) (1)
- [Case report: unusual clinical presentation of a follicular lymphoma]. (2014) (1)
- Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting (2015) (1)
- [Comorbidities in psoriatic arthritis]. (2013) (1)
- Discussion: Treatment of psoriatic arthritis and psoriasis (2005) (1)
- In vivo fluorescence spectroscopy and imaging of ALA-induced endogenous porphyrins in skin after Er:YAG ablation of human stratum corneum (1994) (1)
- [The dermatological indications of laser: beyond cosmetic target.] (2017) (1)
- Supplementary Material for: Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry (2017) (1)
- Idiopathic CD4+ T lymphocytopenia presenting as mycetoma in a patient with a mutation in the cystic fibrosis transmembrane regulator gene. (1996) (1)
- Efficacy and safety of a patch containing adipose-derived stem cells for skin wound healing – results form a comprehensive pre-clinical evaluation program (2022) (1)
- Within-individual comparison of Q-switched Nd:YAG and alexandrite lasers in the treatment of monochromatic black amateur tattoos (1994) (1)
- Problemorientiertes Praktikum (POP) in der Dermatologie: eine Alternative? (1999) (1)
- 15325 Effects of guselkumab on musculoskeletal features in patients with active psoriatic arthritis by baseline skin disease: Results from the phase 3 DISCOVER-1 and DISCOVER-2 studies (2020) (1)
- AB0745 ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL (2019) (1)
- 377 IL-17E favors the recruitment of neutrophils in psoriasis via macrophage activation (2016) (1)
- Schön et al. reply to “Efomycine M: an inhibitor of selectins?” (2006) (1)
- Induction of proinflammatory molecules by anthralin is mediated via reactive oxygen species and activation of NF-KB in human keratinocytes (1998) (1)
- SAT0322 The effect of guselkumab on dactylitis: results from a phase 2 study in patients with active psoriatic arthritis (2018) (1)
- CUTANEOUS DELAYED-TYPE IV-HYPERSENSITIVITY REACTION (DTH) TO HEPARIN AND HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II (HIT) - IS THERE AN ASSOCIATION ? (2007) (1)
- Erratum: Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose? (Experimental Dermatology (2005) vol. 14 (70-80)) (2005) (1)
- [Dermatology: re-defining psoriasis]. (2015) (1)
- [Therapy of psoriasis vulgaris with efalizumab]. (2006) (1)
- Differential expression of heat shock proteins of the HSP70 family in human epidermis (1994) (1)
- Epidermal structure and function. (2015) (1)
- Application of photodynamic therapy in mycosis fungoides (1993) (1)
- Use of delta opioid receptor agonists in the preparation of pharmaceutical compositions, pharmaceutical compositions containing them and their applications in treating tumors. (2006) (0)
- SAT0345 Quality indicators in the care of psoriatic arthritis (2018) (0)
- [New therapy option for problem patients. What is the value of "biologics" in psoriasis?]. (2004) (0)
- Cutis marmorata teleangiectatica congenita with segmental distribution (1996) (0)
- [Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]. (2006) (0)
- 33064 Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: A detailed analysis of SF-36 vitality scores from the VOYAGE 2 study (2022) (0)
- Biologics in Psoriasis (2007) (0)
- [Photodynamic therapy at the threshold of clinical use in disseminated dermatoses]. (1996) (0)
- 207 IL-17E (IL-25) alters epidermal homeostasis in a matter distinct from IL-17A (2019) (0)
- A 41 year old man with an itchy rash (2011) (0)
- [From competition to consultation]. (2013) (0)
- 27529 Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials (2021) (0)
- AB0896 Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis (2022) (0)
- [Fumarates - far more than a dietary supplement]. (2018) (0)
- Analysis of the T cell receptor Vα and Vβ repertoire in psoriasis (1994) (0)
- AB0783 RELATIVE IMPACT OF JOINT AND SKIN SYMPTOMS ON QUALITY OF LIFE AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS (PSA) PATIENTS (2019) (0)
- The psoriasis xenograft SCID mouse model: a tool in translational research (2012) (0)
- Author index (2005) (0)
- AB0893 An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis (2022) (0)
- [Skin symptoms of psoriasis associated with spondylarthropathies]. (2016) (0)
- High incidence of heparin-induced allergic skin reactions in pregnancy (2011) (0)
- 362 The role for epidermal αV integrin complexes in the pathogenesis of psoriatic inflammation (2022) (0)
- 27851 Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2 (2021) (0)
- AB0125 IL-25 PARTICIPATES IN KERATINOCYTE-DRIVEN DERMAL MATRIX TURNOVER AND IS REDUCED IN SYSTEMIC SCLEROSIS (SSc) EPIDERMIS (2022) (0)
- [Learning from each other, treating together]. (2021) (0)
- Who will treat inflammatory skin diseases in the year 2020? (2018) (0)
- Use of GABA B receptor selective agonists for the treatment of inflammatory skin diseases (2007) (0)
- POS0082 A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARGETS FOR SKIN AND JOINTS: POOLED RESULTS FROM THE GUSELKUMAB DISCOVER-1 AND DISCOVER-2 STUDIES (2022) (0)
- P256 Treatment of psoriasis resistant to other modalities by topical photodynamic therapy (1997) (0)
- Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial (Preprint) (2018) (0)
- 27847 Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naïve patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study (2021) (0)
- Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry (2019) (0)
- Psoriasis-SCID-Maus-Modell (2006) (0)
- AB0526 SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES (2021) (0)
- [A plethora of choices: treating actinic keratoses]. (2020) (0)
- [Tender livid papules]. (2004) (0)
- SAT0289 THE INS AND OUTS OF EPIDERMAL DYSFUNCTION IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM A NOVEL TISSUE ENGINEERED EPIDERMAL EQUIVALENT FROM SSC KERATINOCYTES (2020) (0)
- P027 Nail varnish allergy — A diagnosis easy to miss (1997) (0)
- [Erythema scarlatiniforme desquamtivum recidivans or Féréol-Besnier disease: an uncommon condition]. (2013) (0)
- Safety of systemic psoriasis treatments evaluated in the Swiss Dermatology Network for Targeted Therapies (SDNTT) (2017) (0)
- [A beardless 34-year-old male patient]. (2004) (0)
- P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial (2020) (0)
- LB1027 An adipose-derived stem cell-engineered patch represents a promising treatment for chronic wounds (2022) (0)
- Contents Vol. 232, 2016 (2017) (0)
- [Pre-auricular tumors in an infant. Differential diagnosis of neuroectodermal syndromes]. (2004) (0)
- [Papules on the right lower leg of an African girl]. (2006) (0)
- Skewed T cell receptor Vβ usage in nickel expanded peripheral blood T cells is due to an increase of nickel specific T cells (1994) (0)
- POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR (2021) (0)
- Neue Therapieoption fur Problempatienten. Was bringen "Biologics" bei Psoriasis? (2004) (0)
- Adhesion Receptors in Normal Skin and Cutaneous Malignant Lymphomas: Pathophysiological and Clinical Correlations (1994) (0)
- Comprar Biologics in General Medicine | Boehncke, W.-H. | 9783540290179 | Springer (2007) (0)
- POS1015 SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE BIO-NAÏVE OR TNFi-EXPERIENCED: POOLED RESULTS FROM 4 RANDOMIZED CLINICAL TRIALS THROUGH 2 YEARS (2022) (0)
- 037 Safety of systemic psoriasis treatments evaluated in the Swiss Dermatology Network for Targeted Therapies (SDNTT) AutoreactiveB-cellsphenotypeanalysisinpemphiguspatientsbeforeandafteranti-CD20treatment Evaluation of mitochondria-organelle peptides versus nano-sized cellular extracts in aesthetic (2017) (0)
- [Dermatology - the key to ensure a good long term clinical response]. (2016) (0)
- IDIOPATHIC CD4+T LYMPHOCYTOPENIA PRESENTING AS MYCETOMA IN A PATIENT WITH A MUTATION IN A PATIENT WITH A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR GENE (1996) (0)
- [Heparins and skin reactions: from diagnostic to management]. (2013) (0)
- Human herpesvirus-8 DNA in an immunocompetent patient with multifocal anglosarcoma of the face and scalp (1998) (0)
- The T-cell receptor Vbeta repertoire of nickel-specific T cells. (1998) (0)
- Molecular modelling of defensin bound to HLA- DR4 (1998) (0)
- FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES (2019) (0)
- [A case of « peau d'orange » in the absence of cancer]. (2019) (0)
- 385 IL-17E activates M2 macrophages to produce IL-8 in a p38 dependent manner and favor the recruitment of neutrophils in psoriatic skin (2017) (0)
- Elevating the Standard of Care for Patients with Psoriasis: ‘Calls to Action’ from Epicensus, a Multistakeholder Pan-European Initiative (2022) (0)
- Inflammation modulates intercellular adhesion and mechanotransduction in human epidermis via ROCK2 (2022) (0)
- [Cytokines IL-17, an expanding family used as a target for innovative anti-inflammatory therapies]. (2020) (0)
- THU0306 Clinical specialty setting as a determinant for disease management in patients with psoriatic arthritis: results from loop, a cross-sectional, multi-country, observational study (2018) (0)
- >>> Diagnose: Cutis verticis gyrata (2004) (0)
- Controversies in experimental dermatology. Is psoriasis a T-cell disease? Commentaries (2000) (0)
- [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept]. (2005) (0)
- [Nail changes : diagnostic considerations in everyday medical general practice]. (2017) (0)
- Insulin Resistance may be a Central Pathogenetic Mechanism in the Development of Psoriatic Plaques (2012) (0)
- [The role of bacterial superantigens in pathophysiology of the skin]. (1999) (0)
- AB0749 Impact of Patient Perception of Psoriasis and Psoriatic Arthritis Severity on Patient-Reported Outcomes: An Analysis from The Adelphi Database (2016) (0)
- Nordic Psoriasis Debate 2011: Managing Psoriasis - How Can I Improve Care for my Patients? An Interactive Debate on New Treatment Options for Psoriasis (2012) (0)
- AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR (2021) (0)
- Announcement of the winners of the 1997 Munksgaard and Journal of Cutaneous Pathology Prize (1998) (0)
- [100 years of Dermatology in French-speaking Switzerland]. (2014) (0)
- Adipose-Derived Stromal Cells within a Gelatin Matrix Acquire Enhanced Regenerative and Angiogenic Properties: A Pre-Clinical Study for Application to Chronic Wounds (2023) (0)
- Staphylococcal enterotoxin a induces epidermal changes distinct from staphylococcal enterotoxins B and C in the SCID-hu xenogeneic transplantation model (1998) (0)
- [Psoriatic arthritis: important aspects for the dermatological practice]. (2021) (0)
- 113 Psoriatic inflammation modulates mechanotransduction and cell adhesion in human epidermis (2021) (0)
- Evaluation for Comorbidities Important in Psoriasis (2014) (0)
- [Child with atopy]. (2004) (0)
- Phenotypic Heterogeneity of the Dermal Monocyte/Macrophage System (2019) (0)
- [Switching from atopic dermatitis to psoriasis - and back]. (2021) (0)
- Supplementary Material for: Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT (2017) (0)
- Evidence for a psoriasis susceptibility gene linked to HLA-Cw6 in the extended haplotype HLA -DQB1∗0303, -DQA1∗0201, -DRB1∗0701, -B57, -Cw6 (1994) (0)
- [Comorbidities in psoriasic arthritis]. (2014) (0)
- PO-65 Incidence and causes of heparin-induced skin lesions – results of a prospective investigation (2010) (0)
- PO-74 Allergic skin lesions are a rare adverse event under anticoagulant therapy with fondaparinux – results of a prospective investigation (2010) (0)
- [Repurposing of betablockers in dermatology]. (2018) (0)
- Acknowledgement to Referees for Dermatology 2016 (2017) (0)
- Expression of Basal-Cell Adhesion Molecule (B-CAM) in Human Epidermis (2001) (0)
- 042 Evaluation of mitochondria-organelle peptides versus nano-sized cellular extracts in aesthetic dermatology: Comparative case study (2017) (0)
- SAT0387 CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (2019) (0)
- Induction of acantholytic blisters by autoantibodies from pemphigus patients in the SCID-hu xenogeneic transplantation model (1998) (0)
- Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study (2023) (0)
- Application of photodynamic therpy in psoriasis (1993) (0)
- 369 An Adipose-derived Stem Cell-engineered matrix represents a promising treatment for chronic wounds (2021) (0)
- Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis (2022) (0)
- Paradoxical nail psoriasis induced by the IL-17A inhibitor ixekizumab in palmoplantar pustulosis. (2023) (0)
- FRI0440 THE EFFECT OF GUSELKUMAB ON PASDAS, GRACE INDEX, MCPDAI, AND DAPSA: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (2019) (0)
- [Progressive alopecia with pruritus]. (2004) (0)
- Monozygotic twins concordantly affected by psoriasis exhibit a similar shift in the T-cell receptor Vβ-repertoire of lesional compared to circulating lymphocytes (1996) (0)
- Supplementary Material for: Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris (2016) (0)
- DRUG EVALUATION Etanercept: a soluble TNF-α receptor in the treatment of psoriasis (2007) (0)
This paper list is powered by the following services: